Yeast Infection Treatment Market Report 2026

The yeast infection treatment market size has grown strongly in recent years. It will grow from $4.62 billion in 2025 to $4.88 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing prevalence of fungal infections, widespread availability of antifungal medications, growth of retail pharmacy distribution, increased awareness of genital and oral candidiasis, expansion of topical antifungal formulations.

The yeast infection treatment market size is expected to see strong growth in the next few years. It will grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing focus on resistant candida strains, rising demand for long-term management solutions, expansion of online pharmacy channels, growing development of novel antifungal agents, increasing emphasis on patient-centric treatment approaches. Major trends in the forecast period include increasing adoption of combination antifungal therapies, growing demand for over-the-counter treatment options, expansion of probiotic-based adjunct therapies, rising focus on recurrence prevention strategies, improved patient awareness and diagnosis.

The rising prevalence of autoimmune diseases is expected to drive the growth of the yeast infection treatment market going forward. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells, tissues, and organs, impairing bodily function and potentially becoming life-threatening. Yeast infection treatments help manage and prevent complications associated with autoimmune conditions by addressing recurrent yeast infections, which are often linked to certain autoimmune syndromes, and potentially modulating immune responses through fungal infection management in affected patients. For instance, in November 2023, according to the Multiple Sclerosis International Federation (MSIF), a UK-based nonprofit organization focused on global MS research and advocacy, approximately 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune disease, in 2023. Therefore, the increasing prevalence of autoimmune diseases is fueling growth in the yeast infection treatment market.

Key companies in the yeast infection treatment market are focusing on next-generation antifungal therapies as an advanced pharmaceutical innovation to improve treatment efficacy, patient outcomes, and long-term recurrence management. Advanced antifungal therapies target specific fungal mechanisms, such as enzyme inhibition, more selectively and effectively than older broad-spectrum drugs, offering higher cure rates, fewer side effects, and reduced recurrence. For instance, in February 2024, Mycovia Pharmaceuticals Inc, a US-based biopharmaceutical company, in collaboration with Jiangsu Hengrui Pharmaceuticals Co Ltd, a China-based pharmaceutical firm specializing in innovative drug research and commercialization, launched VIVJOA (oteseconazole) capsules, a next-generation oral antifungal for severe vulvovaginal candidiasis. VIVJOA features a short two-day oral course, selective inhibition of the fungal CYP51 enzyme minimizing effects on human enzymes, and improved overall and mycological cure rates compared with fluconazole. This therapy enhances treatment effectiveness, provides rapid symptom relief, and lowers recurrence risk, strengthening the value of prescription-grade yeast infection treatments.

In March 2023, GlaxoSmithKline Plc, a UK-based biopharmaceutical company, partnered with Scynexis to develop Brexafemme (isavuconazonium sulfate) for treating vaginal yeast infections. This partnership aims to significantly improve the availability and accessibility of this innovative treatment, particularly benefiting patients with hard-to-treat infections caused by resistant fungal strains. Scynexis is a US-based biotechnology company focused on developing therapies for difficult-to-treat infections, especially fungal infections.

Major companies operating in the yeast infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Cipla, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Brundavan Laboratories Private Limited, Prestige Consumer Healthcare Inc., Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Johnson & Johnson, GlaxoSmithKline plc, Gilead Sciences Inc., SCYNEXIS Inc., Leadiant Biosciences Inc.

North America was the largest region in the yeast infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the yeast infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the yeast infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the yeast infection treatment market by increasing costs of imported active pharmaceutical ingredients, excipients, packaging materials, and formulation equipment. Pharmaceutical manufacturers and distributors in North America and Europe are most affected due to dependence on global supply chains, while Asia-Pacific faces cost pressure on bulk drug exports. These tariffs are increasing drug prices and affecting affordability in retail and hospital settings. However, they are also encouraging domestic API manufacturing, regional drug formulation, and supply chain diversification that supports long-term market resilience.

The yeast infection treatment market research report is one of a series of new reports that provides yeast infection treatment market statistics, including yeast infection treatment industry global market size, regional shares, competitors with a yeast infection treatment market share, detailed yeast infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the yeast infection treatment industry. This yeast infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Yeast infection treatment refers to medications used to manage and resolve infections caused by the overgrowth of the Candida fungus, commonly called yeast infections. These infections, also known as candidiasis, can affect various parts of the body, including the mouth (oral thrush), genitals (vaginal yeast infection), skin, and other mucous membranes. The treatments are designed to relieve the symptoms associated with these infections.

The primary types of yeast infection treatments are powders, creams or ointments, tablets or capsules, and others. Treatments may include medical therapies or, in some cases, surgical interventions. They are indicated for conditions such as genital candidiasis, invasive candidiasis, oropharyngeal or esophageal candidiasis (thrush), and others. Administration routes include oral, topical, intravenous (IV), intramuscular (IM), and others. These treatments are available through retail pharmacies, hospital pharmacies, specialty stores, online platforms, and other distribution channels.

The yeast infection treatment market consists of revenues earned by entities by providing diagnostic testing, personalized treatment plans, telemedicine consultations, educational programs and more. The market value includes the value of related goods sold by the service provider or included within the service offering. The yeast infection treatment market also includes sales of miconazole, terconazole, fluconazole, amphotericin B, itraconazole, and caspofungin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.